PT2346495T - Formulação farmacêutica 514 - Google Patents

Formulação farmacêutica 514

Info

Publication number
PT2346495T
PT2346495T PT97407282T PT09740728T PT2346495T PT 2346495 T PT2346495 T PT 2346495T PT 97407282 T PT97407282 T PT 97407282T PT 09740728 T PT09740728 T PT 09740728T PT 2346495 T PT2346495 T PT 2346495T
Authority
PT
Portugal
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
PT97407282T
Other languages
English (en)
Inventor
Karl Bechtold Michael
Bettina Packhaeuser Claudia
Kay Cahill Julie
Maren Fastnacht Katja
Harald Liepold Bernd
James Lennon Kieran
Steitz Benedikt
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41396997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2346495(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of PT2346495T publication Critical patent/PT2346495T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PT97407282T 2008-10-07 2009-10-05 Formulação farmacêutica 514 PT2346495T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10334708P 2008-10-07 2008-10-07

Publications (1)

Publication Number Publication Date
PT2346495T true PT2346495T (pt) 2016-11-11

Family

ID=41396997

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97407282T PT2346495T (pt) 2008-10-07 2009-10-05 Formulação farmacêutica 514

Country Status (43)

Country Link
US (11) US8475842B2 (pt)
EP (1) EP2346495B2 (pt)
JP (1) JP5524220B2 (pt)
KR (1) KR101668499B1 (pt)
CN (1) CN102238945B (pt)
AR (2) AR073792A1 (pt)
AU (1) AU2009300866B2 (pt)
BR (2) BR122021018683B1 (pt)
CA (1) CA2737400C (pt)
CL (1) CL2011000774A1 (pt)
CO (1) CO6361906A2 (pt)
CR (1) CR20110186A (pt)
CU (1) CU24032B1 (pt)
CY (2) CY1118190T1 (pt)
DK (1) DK2346495T4 (pt)
DO (1) DOP2011000094A (pt)
EA (1) EA020783B1 (pt)
EC (1) ECSP11010960A (pt)
ES (1) ES2598178T5 (pt)
FI (1) FI2346495T4 (pt)
HK (1) HK1158528A1 (pt)
HN (1) HN2011000947A (pt)
HR (1) HRP20161154T4 (pt)
HU (2) HUE030800T2 (pt)
IL (1) IL211809A (pt)
LT (2) LT2346495T (pt)
ME (1) ME02640B (pt)
MX (1) MX2011003740A (pt)
MY (1) MY160340A (pt)
NI (1) NI201100070A (pt)
NO (1) NO2018038I1 (pt)
NZ (1) NZ592719A (pt)
PE (1) PE20110893A1 (pt)
PL (1) PL2346495T3 (pt)
PT (1) PT2346495T (pt)
RS (1) RS55157B2 (pt)
SA (1) SA109300599B1 (pt)
SI (1) SI2346495T2 (pt)
TW (1) TWI461418B (pt)
UA (1) UA106878C2 (pt)
UY (1) UY32162A (pt)
WO (1) WO2010041051A1 (pt)
ZA (1) ZA201103333B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
NZ605434A (en) 2010-06-09 2014-03-28 Abbvie Bahamas Ltd Solid dispersions containing kinase inhibitors
CN103052382B (zh) * 2010-07-14 2014-10-22 千寿制药株式会社 α-酮酰胺衍生物的固体分散体
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
BR112013009093B1 (pt) 2010-10-29 2022-04-19 Abbvie Inc Processo para a preparação de uma dispersão sólida contendo um agente indutor de apoptose
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
NO2643322T3 (pt) 2010-11-23 2018-01-27
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
AR088936A1 (es) 2011-11-23 2014-07-16 Novartis Ag Formulaciones farmaceuticas
NL2009367C2 (en) * 2012-08-27 2014-03-03 Stichting Vu Vumc Microscopic imaging apparatus and method to detect a microscopic image.
NZ708255A (en) 2012-12-31 2016-08-26 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CN104434809B (zh) * 2014-12-10 2018-10-16 北京科莱博医药开发有限责任公司 一种奥拉帕尼固体分散体制剂及其制备方法
CN105777651A (zh) * 2015-01-13 2016-07-20 江苏豪森药业集团有限公司 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
CN106265580B (zh) * 2015-05-18 2020-09-08 中国科学院上海药物研究所 Somcl-9112固体分散体、其制备方法及包含其的somcl-9112固体制剂
CN105439961A (zh) * 2015-06-12 2016-03-30 苏州晶云药物科技有限公司 奥拉帕尼的晶型i及其制备方法
US20170105937A1 (en) * 2015-10-16 2017-04-20 Cadila Healthcare Limited Olaparib co-precipitate and preparation method thereof
CN105254572A (zh) * 2015-11-09 2016-01-20 北京科莱博医药开发有限责任公司 一种奥拉帕尼的晶型及其制备方法和应用
ITUB20159206A1 (it) * 2015-12-22 2017-06-22 Olon Spa Forme cristalline e amorfe di olaparib
US20170204067A1 (en) 2016-01-14 2017-07-20 Scinopharm Taiwan, Ltd. Crystalline forms of olaparib and manufacturing processes therefor
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
CN108201536A (zh) * 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
AU2018282883B2 (en) * 2017-06-12 2024-03-28 Protein Dynamic Solutions, Inc. Method and system for analysis of crystals and crystallization
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
CN109293576A (zh) * 2018-11-08 2019-02-01 威海贯标信息科技有限公司 一种小粒度奥拉帕尼的制备方法
CN110840845B (zh) * 2018-11-16 2022-10-21 江苏恒瑞医药股份有限公司 一种包含parp抑制剂的药物组合物
CN110013466B (zh) * 2019-05-28 2021-11-30 天津中医药大学 一种小檗红碱固体分散体粉末及制备方法及应用
US10703728B1 (en) * 2019-06-18 2020-07-07 Scinopharm Taiwan, Ltd. Crystalline form of olaparib and a process for preparing the same
CN115175668A (zh) * 2019-12-20 2022-10-11 三养控股公司 具有改善的奥拉帕尼的溶解度和生物利用率的组合物
CN116234803A (zh) 2019-12-23 2023-06-06 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
BR112022013492A2 (pt) 2020-01-09 2022-09-13 Astrazeneca Ab Terapia de combinação para tratar câncer
CN113288859A (zh) 2020-02-21 2021-08-24 上海宣泰医药科技股份有限公司 奥拉帕尼药物组合物及其制剂、制备方法和用途
CN113350349B (zh) * 2020-03-04 2022-11-11 中国科学院上海药物研究所 奥拉帕尼溶出增强组合物
CN116710424A (zh) 2020-09-16 2023-09-05 努福米克斯技术有限公司 奥拉帕利草酸共晶体及其药学用途
KR20220077094A (ko) * 2020-12-01 2022-06-08 주식회사 삼양홀딩스 안정성 및 생체이용율이 개선된 올라파립 고체 분산체 조성물
CN112843007A (zh) * 2021-02-04 2021-05-28 石药集团中奇制药技术（石家庄）有限公司 一种奥拉帕利片
WO2022258625A1 (en) * 2021-06-07 2022-12-15 Zerion Pharma ApS Co-amorphous forms for use in cancer therapy
US20230183185A1 (en) 2021-11-10 2023-06-15 Nufromix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
WO2023174948A2 (en) * 2022-03-14 2023-09-21 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics and uses thereof
WO2024012572A1 (zh) * 2022-07-14 2024-01-18 西藏海思科制药有限公司 一种杂芳基衍生物的药物组合物及其在医药上的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2143745A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en) 1974-03-01 1975-09-26 Delalande Sa 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en) 1978-05-31 1979-12-10 Asahi Chemical Ind Dry picture forming material
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
JPS58164577A (ja) 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en) 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
EP0222191B1 (de) 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8610018D0 (en) 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
DE3640641A1 (de) 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ZA882639B (en) 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
JP2786896B2 (ja) 1988-08-19 1998-08-13 ワーナー―ランバート・コンパニー 置換されたジヒドロイソキノリノンおよび関連化合物
DE69019774T2 (de) 1989-03-28 1995-11-09 Nisshin Flour Milling Co Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
DD287032A5 (de) 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
AU3440693A (en) 1992-01-17 1993-08-03 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin II antagonists
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
JPH08502973A (ja) 1992-11-02 1996-04-02 メルク エンド カンパニー インコーポレーテッド ニューロテンシンアンタゴニストとしての置換フタラジノン
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
CN1172502A (zh) 1994-08-12 1998-02-04 亿万遗传股份有限公司 17q连锁的乳房癌和卵巢癌易患性基因的体内突变和多态性
ES2164136T5 (es) 1994-08-12 2009-02-16 The University Of Utah Research Foundation Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q.
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
EP0721286A3 (en) 1995-01-09 2000-07-26 Matsushita Electric Industrial Co., Ltd. Video signal decoding apparatus with artifact reduction
ES2194986T3 (es) 1995-04-07 2003-12-01 Schering Corp Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
US6127367A (en) 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc CANCER TREATMENT METHOD
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038664A2 (en) 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
US5880128A (en) 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
EP0934270A1 (en) 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
CN1198614C (zh) 1997-05-13 2005-04-27 奥科特默股份有限公司 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US6060038A (en) 1997-05-15 2000-05-09 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
WO1999008680A1 (en) 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
CA2310250A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
EP1066039A4 (en) 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US20040266784A1 (en) 1998-06-30 2004-12-30 Snutch Terrance P. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6951862B2 (en) 1998-06-30 2005-10-04 Neuromed Technologies, Inc. Calcium channel blockers comprising two benzhydril moieties
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6011035A (en) 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
US20040259866A1 (en) 1998-06-30 2004-12-23 Snutch Terrance P. Calcium channel blockers comprising two benzhydril moieties
US6310059B1 (en) 1998-06-30 2001-10-30 Neuromed Technologies, Inc. Fused ring calcium channel blockers
US20060084660A1 (en) 1998-06-30 2006-04-20 Neuromed Technologies Inc. Calcium channel blockers comprising two benzhydril moieties
US6943168B2 (en) 1998-06-30 2005-09-13 Neuromed Technologies Inc. Calcium channel inhibitors comprising benzhydril spaced from piperazine
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
DE60010476T2 (de) 1999-08-11 2005-04-14 Bristol-Myers Squibb Co. Verfahren zur Herstellung eines C-4-Methylcarbonat-Analogons von Paclitaxel
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2001023390A2 (de) 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindol-derivate, deren herstellung und anwendung
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
DE19963607B4 (de) 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
AU2001240542A1 (en) 2000-02-01 2001-08-14 Basf Aktiengesellschaft Heterocyclic compounds and their use as parp inhibitors
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
US6723733B2 (en) 2000-05-19 2004-04-20 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses
JP4954426B2 (ja) 2000-06-16 2012-06-13 キュリス，インコーポレイテッド 血管形成調節組成物及び利用
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
CA2471715A1 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
CN100348587C (zh) 2002-02-19 2007-11-14 小野药品工业株式会社 稠合哒嗪衍生物化合物和含这些化合物作为活性成份的药物
DE60330442D1 (de) 2002-02-25 2010-01-21 Kudos Pharm Ltd Als atm-inhibitoren geeignete pyranone
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2003093261A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2004220321B2 (en) 2003-03-12 2010-02-25 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) † 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP5545690B2 (ja) 2003-12-01 2014-07-09 クドス ファーマシューティカルズ リミテッド 癌治療のためのｄｎａ損傷修復阻害剤
EP1744751A4 (en) 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US20050227999A1 (en) 2004-04-09 2005-10-13 Neuromed Technologies Inc. Diarylamine derivatives as calcium channel blockers
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
DE102005011822A1 (de) 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
UY30639A1 (es) * 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008083027A1 (en) 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
ES2598178T5 (es) * 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514

Also Published As

Publication number Publication date
NZ592719A (en) 2012-09-28
UY32162A (es) 2010-05-31
US11633396B2 (en) 2023-04-25
US20230346780A1 (en) 2023-11-02
CY1118190T1 (el) 2017-06-28
LTPA2018014I1 (lt) 2018-12-10
FI2346495T4 (fi) 2023-08-31
IL211809A (en) 2014-12-31
ES2598178T3 (es) 2017-01-25
HN2011000947A (es) 2014-02-17
AU2009300866B2 (en) 2013-03-28
BRPI0920604B1 (pt) 2021-11-23
CA2737400C (en) 2016-11-22
SI2346495T1 (sl) 2016-10-28
CO6361906A2 (es) 2012-01-20
US20160008473A1 (en) 2016-01-14
EP2346495B2 (en) 2023-05-24
TWI461418B (zh) 2014-11-21
CY2018030I2 (el) 2019-11-27
KR101668499B1 (ko) 2016-10-21
US8475842B2 (en) 2013-07-02
SI2346495T2 (sl) 2023-10-30
HK1158528A1 (zh) 2012-07-20
US20220249474A1 (en) 2022-08-11
RS55157B1 (sr) 2017-01-31
CL2011000774A1 (es) 2011-08-05
WO2010041051A1 (en) 2010-04-15
HRP20161154T4 (hr) 2023-09-29
EP2346495B1 (en) 2016-07-20
UA106878C2 (uk) 2014-10-27
KR20110066942A (ko) 2011-06-17
JP2012505158A (ja) 2012-03-01
SA109300599B1 (ar) 2014-02-17
HUE030800T2 (en) 2017-05-29
US20100098763A1 (en) 2010-04-22
ZA201103333B (en) 2012-01-25
BR122021018683B1 (pt) 2022-11-16
LT2346495T (lt) 2016-10-10
US20170173010A1 (en) 2017-06-22
MX2011003740A (es) 2011-05-02
CU20110080A7 (es) 2011-12-28
CR20110186A (es) 2011-08-09
ME02640B (me) 2017-06-20
EP2346495A1 (en) 2011-07-27
PL2346495T3 (pl) 2017-02-28
EA020783B1 (ru) 2015-01-30
AU2009300866A1 (en) 2010-04-15
HUS1800043I1 (hu) 2018-11-28
US20180133216A1 (en) 2018-05-17
ECSP11010960A (es) 2011-05-31
PE20110893A1 (es) 2012-01-18
BRPI0920604A2 (pt) 2020-09-15
US20200323847A1 (en) 2020-10-15
ES2598178T5 (es) 2023-12-26
CN102238945B (zh) 2014-10-29
CN102238945A (zh) 2011-11-09
CY2018030I1 (el) 2019-11-27
CU24032B1 (es) 2014-10-02
US20190365751A1 (en) 2019-12-05
US20230338372A1 (en) 2023-10-26
EA201100595A1 (ru) 2011-12-30
DOP2011000094A (es) 2011-07-15
DK2346495T3 (en) 2016-09-26
HRP20161154T1 (hr) 2016-11-18
US20230000862A1 (en) 2023-01-05
IL211809A0 (en) 2011-06-30
US20140066447A1 (en) 2014-03-06
NO2018038I1 (no) 2018-11-07
DK2346495T4 (da) 2023-08-28
AR116035A2 (es) 2021-03-25
CA2737400A1 (en) 2010-04-15
TW201018671A (en) 2010-05-16
MY160340A (en) 2017-02-28
NI201100070A (es) 2012-03-19
RS55157B2 (sr) 2023-10-31
AR073792A1 (es) 2010-12-01
JP5524220B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
HUS1800043I1 (hu) 514 számú gyógyszerkészítmény
GB2450753B (en) New Pharmaceutical formulation
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0814695D0 (en) Pharmaceutical compositions
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
PL2323623T3 (pl) Kompozycje farmaceutyczne
GB0614586D0 (en) Pharmaceutical Formulation
ZA201004439B (en) Formulation
EP2306998A4 (en) PHARMACEUTICAL FORMULATION
GB0707463D0 (en) Formulation
HK1156844A1 (en) Pharmaceutical composition 271 271
IL208788A (en) Pharmacy-based formulation
EP2275092A4 (en) PHARMACEUTICAL TAX FORMULATION
GB0715723D0 (en) Formulation
GB0712972D0 (en) Formulation
IL206487A0 (en) Pharmaceutical compositions
ZA200806951B (en) Homeopathy-based formulation
GB0800659D0 (en) Pharmaceutical Compositions
GB0705030D0 (en) Pharmaceutical formulation
GB0805292D0 (en) Pharmaceutical formulation
SI2271321T1 (sl) Farmacevtski sestavek 271
GB0810217D0 (en) Pharmaceutical formulations
GB0813031D0 (en) Pharmaceutical formulations
GB0713093D0 (en) Pharmaceutical formulations
GB0918912D0 (en) Improved medicament formulation